申请人:WisTa Laboratories Ltd.
公开号:US20180078562A1
公开(公告)日:2018-03-22
This disclosure pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiaziniumcompounds”) including Methythioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt-formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). Also disclosed resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment and diagnosis, etc., for example, for tauopathies, Alzheimer's disease (AD), skin cancer, melanoma, viral diseases, bacterial diseases, or protozoal diseases.
本公开涉及化学合成和纯化领域,更具体地涉及合成和纯化某些3,7-二氨基苯并噻嗪-5-ium化合物(以下简称“二氨基苯并噻嗪化合物”),包括氯化甲亚硫胺(MTC)(也称亚甲蓝)。在一种实施例中,该方法依次包括以下步骤:硝基化(NOS);硝酰还原(NR);硫代磺酸形成(TSAF);氧化偶联(OC);Cr(VI)还原(CR);分离和纯化离子性中间体(IAPOZI);环闭合(RC);氯化物盐形成(CSF);其中之一:硫化物处理(ST);二甲基二硫代氨基甲酸盐处理(DT);碳酸盐处理(CT);乙二胺四乙酸盐处理(EDTAT);有机萃取(OE);和重结晶(RX)。还公开了得到的(高纯度)化合物,包括它们的组合物(例如,片剂,胶囊)以及它们在灭活病原体的方法、医疗治疗和诊断方法等方面的应用,例如用于tau病理学、阿尔茨海默病(AD)、皮肤癌、黑色素瘤、病毒性疾病、细菌性疾病或原虫病等。